Table 2 Prevalence of co-existing conditions at baseline and the course of response during five months of follow-up.
Co-existing conditions (n = 296) | Prevalence at baseline n (% of 296) | Not reported at follow-up n (%*) | Lost to follow-up n (%*) | New report at follow-up n (% of 246) | ||||
|---|---|---|---|---|---|---|---|---|
Diabetes | 73 | (24.7) | 6 | (8.2) | 10 | (13.7) | 3 | (1.2) |
COPD or asthma | 32 | (10.8) | 9 | (28.1) | 4 | (12.5) | 5 | (2.0) |
Heart | 67 | (22.7) | 13 | (19.4) | 8 | (11.9) | 8 | (3.3) |
Stroke | 33 | (11.2) | 6 | (18.2) | 5 | (15.2) | 8 | (3.3) |
Hearing impairments | 23 | (7.8) | 10 | (43.5) | 5 | (21.7) | 9 | (3.7) |
Musculoskeletal | 82 | (27.8) | 18 | (22.0) | 15 | (18.3) | 16 | (6.5) |
Cancer | 13 | (4.4) | 2 | (15.4) | 4 | (30.8) | 3 | (1.2) |
Hypertension | 48 | (16.3) | 14 | (29.2) | 11 | (22.9) | 12 | (4.9) |
Gastrointestinal | 15 | (5.1) | 4 | (26.7) | 3 | (20.0) | 6 | (2.4) |